Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis. A BLA was submitted in June 2013 seeking approval for vedolizumab for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). The application submitted for vedolizumab for the treatment of adults with moderately to severely active CD will be reviewed by the FDA under the standard review timeline.  

An application can receive Priority Review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority Review status allows for an eight month review period from the date of submission, compared to the standard review period of 12 months.

"Additional treatment options are needed for ulcerative colitis, and the acceptance for Priority Review of vedolizumab underscores this need," said Karen Lasch, M.D., medical director - GI, Medical Affairs, U.S. Region, Takeda. "Takeda is excited about the potential for vedolizumab and, if approved, the possibility of providing a new treatment option for people with CD and UC."

CD and UC are the two most common types of inflammatory bowel disease (IBD), and can be both painful and debilitating, sometimes leading to serious complications. While CD and UC treatment options are available, many patients may not achieve or maintain remission of their disease. 
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Braeburn ... its current therapeutic focus beyond addiction and ... psychiatric disorders. Braeburn has acquired an implantable, ... antipsychotic risperidone for treatment of schizophrenia from ... acquires global rights to other potential applications ...
(Date:5/1/2015)... -- Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) ... 31, 2015, as well as general business updates. Due ... will be held. Key Highlights , ... increased to $206 million from $119 million for the ... ® (ibrutinib) net product revenue of $247 million ...
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... approvals necessary to complete the acquisition of Paddock ... of generic Rx pharmaceuticals and OTC specialty products. ... C. Papa stated, "We are looking forward to ...
... Corporation ("Unilife" or the "Company") (NASDAQ: UNIS ... completed the validation phase of the Unifill® ready-to-fill (prefilled) ... in the industrialization process for the Unifill syringe. ... completion of all validation tests associated with the Unifill ...
Cached Medicine Technology:Perrigo Provides Update on Acquisition of Paddock Labs 2Perrigo Provides Update on Acquisition of Paddock Labs 3Unilife Successfully Completes Industrialization of Unifill Syringe 2Unilife Successfully Completes Industrialization of Unifill Syringe 3Unilife Successfully Completes Industrialization of Unifill Syringe 4
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has had ... Miranda and Alex Shields to the team. With Neida and ... of combined experience working with dentists to ensure their success. ... 8 years. She was certified as dental assistant from ... attitude and showing the importance of oral hygiene to patients, ...
(Date:5/1/2015)... Jusuru International has been awarded the ... of its flagship nutritional supplement, Liquid BioCell™ Life, and ... name, new logo, new packaging, new products, and new ... to identify and promote programs that serve as examples ... congratulates Jusuru International for their outstanding accomplishments and contributions ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... the fact that uncomplicated twin pregnancies may be more ... ,Researchers of Imperial College London report that normal monochorionic ... deaths. In monochorionic diamniotic twin pregnancy, the twin fetuses ... and often are the most common form of twin ...
... that teenage girls living in temperate countries or colder regions ... they took supplements of Vitamin D in the winter months ... sun is important for formation of the active component of ... would help to strengthen bones for later years. The researchers ...
... According to the article published in The Journal of ... of antibiotics for // acute uncomplicated lower respiratory tract ... is a common complaint in the out patient departments ... is treated. ,The randomized controlled trial was ...
... have identified an enzyme’s new role in aiding joint ... called cathepsin G can regulate the ability of the ... process of inflammatory conditions that can lead to arthritis. ... that can lead to damage of the tissue and ...
... reaction to a common water pollutant called arsenic may not ... out to a gene called CYT19 in people, particularly in ... metal called arsenic. ,Arsenic exposure had long been associated ... bladder, circulatory problems, and neurological disorders. It can enter the ...
... vehicles in the world could run using a pollution free ... from Stanford are just working towards this solution to look ... fuel cells and the hydrogen would reacts with oxygen to ... combustion mechanism and this would be pollution free. A similar ...
Cached Medicine News:Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2Health News:Antibiotics for acute uncomplicated lower respiratory tract infection 2Health News:Pollution Free Hydrogen based fuel for Energy 2Health News:Pollution Free Hydrogen based fuel for Energy 3
... an innovative device designed to be a ... abdominal aortic aneurysms (AAA). It is constructed ... an outer self-expanding Nitinol support structure to ... The function of the endoprosthesis is to ...
... GORE PROCEL Cast Liner (formerly sold as ... their cast wet, thus minimizing discomfort and ... Liner is a waterproof, breathable, washable cast ... stockinette underneath a fiberglass cast. It allows ...
... for bypass grafting or creation of a ... tissue tunnel is of the utmost importance ... the answer for those seeking a high-precision ... minimizes the risk of twisting or kinking ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
Medicine Products: